StocksFundsScreenerSectorsWatchlists
DXCM

DXCM - DexCom Inc Stock Price, Fair Value and News

130.74USD-3.56 (-2.65%)Market Closed

Market Summary

DXCM
USD130.74-3.56
Market Closed
-2.65%

DXCM Alerts

  • 7 major insider sales recently.

DXCM Stock Price

View Fullscreen

DXCM RSI Chart

DXCM Valuation

Market Cap

50.4B

Price/Earnings (Trailing)

93.08

Price/Sales (Trailing)

13.91

EV/EBITDA

54.84

Price/Free Cashflow

98.46

DXCM Price/Sales (Trailing)

DXCM Profitability

Operating Margin

94.62%

EBT Margin

19.61%

Return on Equity

26.18%

Return on Assets

8.64%

Free Cashflow Yield

1.02%

DXCM Fundamentals

DXCM Revenue

Revenue (TTM)

3.6B

Rev. Growth (Yr)

26.9%

Rev. Growth (Qtr)

6.1%

DXCM Earnings

Earnings (TTM)

541.5M

Earnings Growth (Yr)

179.19%

Earnings Growth (Qtr)

112.34%

Breaking Down DXCM Revenue

Last 7 days

-3.8%

Last 30 days

0.1%

Last 90 days

5.5%

Trailing 12 Months

8.2%

How does DXCM drawdown profile look like?

DXCM Financial Health

Current Ratio

2.84

DXCM Investor Care

Buy Backs (1Y)

0.23%

Diluted EPS (TTM)

1.3

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20233.0B3.2B3.4B3.6B
20222.6B2.7B2.8B2.9B
20212.0B2.2B2.3B2.4B
20201.6B1.7B1.8B1.9B
20191.1B1.2B1.4B1.5B
2018760.6M832.5M914.6M1.0B
2017599.4M632.7M668.7M718.5M
2016445.4M489.8M534.2M573.3M
2015285.1M319.2M354.4M402.0M
2014177.1M200.1M226.2M259.0M
2013109.5M121.8M141.6M160.0M
201282.2M84.3M89.1M100.0M
201153.3M62.9M69.5M76.3M
201034.4M39.2M43.9M48.6M
200900029.7M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of DexCom Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 15, 2024
dolan matthew vincent
sold
-274,242
137
-1,990
evp strategy and corporate dev
Apr 08, 2024
sayer kevin r
sold
-6,864,140
138
-49,633
president ceo and chairman
Mar 28, 2024
brown michael jon
sold
-367,472
140
-2,624
evp chief legal officer
Mar 25, 2024
stern sadie
sold
-579,180
140
-4,137
evp chief human resources
Mar 15, 2024
dolan matthew vincent
sold
-547,259
130
-4,203
evp strategy & corp dev
Mar 12, 2024
stern sadie
sold
-2,715,010
133
-20,321
evp chief human resources
Mar 12, 2024
sylvain jereme m
sold
-1,567,360
134
-11,661
evp chief financial officer
Mar 12, 2024
sayer kevin r
sold
-10,802,800
133
-81,007
president ceo and chairman
Mar 12, 2024
leach jacob steven
sold
-1,967,640
134
-14,639
evp chief operating officer
Mar 12, 2024
brown michael jon
sold
-1,182,680
134
-8,799
evp chief legal officer

1–10 of 50

Which funds bought or sold DXCM recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 18, 2024
FARMERS & MERCHANTS INVESTMENTS INC
unchanged
-
3,696
35,091
-%
Apr 18, 2024
Edmonds Duncan Registered Investment Advisors, LLC
reduced
-25.08
-50,360
259,369
0.06%
Apr 18, 2024
Nvest Financial, LLC
unchanged
-
37,635
357,291
0.24%
Apr 18, 2024
MV CAPITAL MANAGEMENT, INC.
added
1.44
4,602
38,975
-%
Apr 18, 2024
Diversified Trust Co
added
0.15
876,430
8,214,370
0.25%
Apr 18, 2024
Allspring Global Investments Holdings, LLC
added
0.33
19,349,100
178,751,000
0.28%
Apr 18, 2024
VAUGHAN NELSON INVESTMENT MANAGEMENT, L.P.
added
21.28
51,448,000
196,117,000
1.72%
Apr 18, 2024
Capital Advisors, Ltd. LLC
added
1.29
9,000
76,000
0.01%
Apr 18, 2024
Congress Wealth Management LLC / DE /
added
0.57
2,582,240
23,392,800
0.40%
Apr 18, 2024
SteelPeak Wealth, LLC
sold off
-100
-421,906
-
-%

1–10 of 48

Are Funds Buying or Selling DXCM?

Are funds buying DXCM calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own DXCM
No. of Funds

Unveiling DexCom Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
11.51%
44,467,151
SC 13G/A
Jan 25, 2024
blackrock inc.
8.5%
32,851,473
SC 13G/A
Feb 10, 2023
blackrock inc.
8.7%
33,535,680
SC 13G/A
Feb 09, 2023
vanguard group inc
11.34%
43,819,836
SC 13G/A
Jan 27, 2023
blackrock inc.
8.7%
33,882,680
SC 13G/A
Jan 25, 2023
blackrock inc.
8.8%
33,882,680
SC 13G/A
Feb 09, 2022
vanguard group inc
10.74%
10,410,319
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 08, 2022
blackrock inc.
8.4%
8,128,454
SC 13G/A
Dec 06, 2021
baillie gifford & co
4.85%
4,700,380
SC 13G/A

Recent SEC filings of DexCom Inc

View All Filings
Date Filed Form Type Document
Apr 16, 2024
4
Insider Trading
Apr 15, 2024
144
Notice of Insider Sale Intent
Apr 10, 2024
4
Insider Trading
Apr 08, 2024
144
Notice of Insider Sale Intent
Apr 01, 2024
144
Notice of Insider Sale Intent
Mar 29, 2024
4
Insider Trading
Mar 28, 2024
144
Notice of Insider Sale Intent
Mar 26, 2024
4
Insider Trading
Mar 25, 2024
144
Notice of Insider Sale Intent
Mar 25, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to DexCom Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
186.2B
40.1B
-6.98% -6.26%
32.53
4.64
-8.12% -17.45%
67.7B
19.5B
-2.95% -9.93%
53.87
3.47
4.02% -22.04%
22.5B
3.9B
-4.96% -15.40%
50.45
5.81
3.42% 23.09%
20.0B
14.8B
-5.44% -9.06%
7.55
1.35
2.12% 209.17%
MID-CAP
9.2B
3.5B
-0.25% 17.23%
32.32
2.64
4.97% 18.89%
9.1B
12.3B
-5.97% -15.68%
21.9
0.74
-2.44% -22.68%
8.2B
2.7B
-16.50% -42.23%
-12.81
3.06
-4.68% 82.43%
6.3B
4.0B
-8.09% -25.03%
-47.02
1.6
1.10% 85.84%
3.4B
366.4M
-2.40% 13.34%
-562.39
9.32
33.86% 89.83%
2.3B
6.6B
-5.10% -3.56%
12.04
0.35
2.78% -0.87%
SMALL-CAP
1.2B
3.2B
-10.67% -21.18%
-1.83
0.39
7.73% -1066.14%
383.3M
166.7M
0.43% -6.80%
-4.64
2.3
6.67% -456.34%
250.3M
324.0M
10.27% -31.54%
-1.3
0.77
-3.19% -337.41%
45.7M
52.3M
-23.89% -53.56%
-2.44
0.87
17.61% 19.28%
3.8M
3.7M
-12.80% 240.48%
-0.31
1.02
5.77% 8.23%

DexCom Inc News

Latest updates
MarketWatch29 hours ago
Zacks Investment Research37 hours ago
MarketBeat17 Apr 202401:51 am
Yahoo Finance15 Apr 202410:15 pm

DexCom Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue6.1%1,035975871742815770696629698650595505569501452405463396336281338
Gross Profit5.3%657623546463541494450398473447417344399340284257309247207169223
Operating Expenses5.2%440418418415416347373357472329316298295246216223208191207183387
  S&GA Expenses8.5%309285297295305235249219237199187189173159136150129124138124112
  R&D Expenses3.6%13613111911911611012213615012912910911988.0080.0073.0079.0067.0069.0059.0058.00
EBITDA Margin-0.25*-0.21*0.20*0.19*0.16*0.14*0.15*0.15*0.20*0.20*0.20*0.20*--------
Interest Expenses---6.005.00-1.705.005.005.00-2.505.005.005.00-42.4024.0020.0015.0015.0015.0015.0015.008.00
Income Taxes-108.4%-10.1012043.0016.0041.0045.0024.00-61.2012.0025.0019.00-15.20-2573.00-0.103.002.00-1.000.003.00
Earnings Before Taxes2.4%24624015965.0013314675.0036.006.0011297.0041.0015475.0046.0022.0094.0046.00-9.30-26.60-176
EBT Margin11.7%0.20*0.18*0.16*0.14*0.13*0.09*0.09*0.10*0.10*0.17*0.17*0.16*---------
Net Income112.3%25612111649.0092.0010151.0097.00-5.3087.0078.0057.0041172.0046.0020.0093.0046.00-10.50-26.90-179
Net Income Margin34.9%0.15*0.11*0.11*0.10*0.12*0.09*0.09*0.10*0.09*0.27*0.28*0.29*---------
Free Cashflow-62.9%81.0021913181.0069.0018581.00-30.6026.00139-39.60-71.90---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-5.0%6,2656,5966,8215,5165,3924,8995,2175,0574,9334,7764,5044,3904,2913,8333,5222,4482,3952,1862,0661,9741,916
  Current Assets-5.8%4,4264,6985,0033,7673,6693,3993,8093,7473,6843,6563,4743,4453,4253,2373,0331,9961,9691,8161,7441,6911,700
    Cash Equivalents-12.0%5666441,1956236426987357161,0531,4441,1597348186745305854463967091,2851,137
  Inventory12.2%56049942136630731134034235735131929023520116514212012011810171.00
  Net PPE----1,0761,0561,003943857802742676590515462384346321301253221183
  Goodwill-0.4%25.0025.0026.0026.0026.0025.0026.0027.0027.0024.0019.0019.0019.0019.0019.0019.0019.0018.0019.0019.0019.00
Liabilities-3.1%4,1964,3284,7203,2833,2603,0752,9622,8682,8912,6402,5062,4872,4642,3342,1681,5131,5121,4211,3781,3051,253
  Current Liabilities-7.3%1,5561,6792,0701,8651,839901807711721735601604614506400343360322288235222
Shareholder's Equity-8.8%2,0692,2682,1002,2332,1321,8252,2562,1892,0421,9121,7551,6451,5521,4991,354935883764688669663
  Retained Earnings33.5%1,021765644529480388287236139-28.00-98.90-161-78.20-557-629-675-695-788-834-823-798
  Additional Paid-In Capital-2.9%3,5153,6182,2692,3062,2582,0722,0291,9972,1092,3222,1942,1621,7272,1542,0801,7071,6761,6521,6201,5911,561
Shares Outstanding-0.3%385386386388386390393389387387386385---------
Float---49,400---29,100---41,100---38,500---13,557--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-50.4%133,600269,200190,300155,400132,500293,200172,80071,000105,800247,30061,60027,800172,000147,600154,1001,900143,70094,50064,50011,80033,700
  Share Based Compensation-5.4%36,90039,00039,70035,20034,00030,80032,60029,10026,30027,50031,60028,00034,10030,70030,70023,90023,60024,40029,70025,00024,600
Cashflow From Investing331.1%414,900-179,500-555,900-186,700-194,100229,300-144,900-411,800-496,10029,000363,200-112,200-24,000-9,300-1,115,300130,600-94,300-412,800-639,400131,30030,900
Cashflow From Financing0.9%-631,900-637,400939,50011,200-1,000-552,500-4,3005,300-80010,800-400800-4,9004,500906,0006,500-1006,000-1004,900701,600
  Buy Backs-500,000----557,700---------------

DXCM Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Revenue$ 3,622.3$ 2,909.8$ 2,448.5
Cost of sales1,333.41,026.7768.0
Gross profit2,288.91,883.11,680.5
Operating expenses:   
Research and development505.8484.2517.1
Collaborative research and development fee0.00.087.1
Selling, general and administrative1,185.41,007.7810.5
Total operating expenses1,691.21,491.91,414.7
Operating income597.7391.2265.8
Other income (expense), net112.7(0.4)(9.0)
Income before income taxes710.4390.8256.8
Income tax expense168.949.639.9
Net income$ 541.5$ 341.2$ 216.9
Basic net income per share (in usd per share)$ 1.40$ 0.88$ 0.56
Shares used to compute basic net income per share (in shares)386.0389.4386.9
Diluted net income per share (in usd per share)$ 1.30$ 0.82$ 0.53
Shares used to compute diluted net income per share (in shares)425.5427.5428.8

DXCM Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 566.3$ 642.3
Short-term marketable securities2,157.81,813.9
Accounts receivable, net973.9713.3
Inventory559.6306.7
Prepaid and other current assets168.3192.6
Total current assets4,425.93,668.8
Property and equipment, net1,113.11,055.6
Operating lease right-of-use assets71.480.0
Goodwill25.225.7
Intangibles, net134.5173.3
Deferred tax assets419.4341.2
Other assets75.047.1
Total assets6,264.55,391.7
Current liabilities:  
Accounts payable and accrued liabilities1,345.5901.8
Accrued payroll and related expenses171.0134.3
Current portion of long-term senior convertible notes0.0772.6
Short-term operating lease liabilities21.120.5
Deferred revenue18.410.1
Total current liabilities1,556.01,839.3
Long-term senior convertible notes2,434.21,197.7
Long-term operating lease liabilities80.194.6
Other long-term liabilities125.6128.3
Total liabilities4,195.93,259.9
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at December 31, 2023 and December 31, 20220.00.0
Common stock, $0.001 par value, 800.0 million shares authorized; 407.2 million and 385.4 million shares issued and outstanding, respectively, at December 31, 2023; and 393.2 million and 386.3 million shares issued and outstanding, respectively, at December 31, 20220.40.4
Additional paid-in capital3,514.62,258.1
Accumulated other comprehensive loss(16.7)(11.6)
Retained earnings1,021.4479.9
Treasury stock, at cost; 21.8 million shares at December 31, 2023 and 6.9 million shares at December 31, 2022(2,451.1)(595.0)
Total stockholders’ equity2,068.62,131.8
Total liabilities and stockholders’ equity$ 6,264.5$ 5,391.7
DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
 CEO
 WEBSITEdexcom.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES7500

DexCom Inc Frequently Asked Questions


What is the ticker symbol for DexCom Inc? What does DXCM stand for in stocks?

DXCM is the stock ticker symbol of DexCom Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of DexCom Inc (DXCM)?

As of Thu Apr 18 2024, market cap of DexCom Inc is 51.77 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DXCM stock?

You can check DXCM's fair value in chart for subscribers.

What is the fair value of DXCM stock?

You can check DXCM's fair value in chart for subscribers. The fair value of DexCom Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of DexCom Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DXCM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is DexCom Inc a good stock to buy?

The fair value guage provides a quick view whether DXCM is over valued or under valued. Whether DexCom Inc is cheap or expensive depends on the assumptions which impact DexCom Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DXCM.

What is DexCom Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 18 2024, DXCM's PE ratio (Price to Earnings) is 95.61 and Price to Sales (PS) ratio is 14.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DXCM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on DexCom Inc's stock?

In the past 10 years, DexCom Inc has provided 0.31 (multiply by 100 for percentage) rate of return.